We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+13.8%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$14.5B
AUM Growth
+$1.96B
Cap. Flow
+$582M
Cap. Flow %
4.02%
Top 10 Hldgs %
31.8%
Holding
146
New
31
Increased
52
Reduced
23
Closed
24

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$319M
2
IMMU
Immunomedics Inc
IMMU
+$296M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$216M
4
NYT icon
New York Times
NYT
+$130M
5
HLT icon
Hilton Worldwide
HLT
+$129M

Top Sells

Rank Stock Value
1
PPLI
People Inc
PPLI
+$456M
2
WUBA
58.com Inc
WUBA
+$268M
3
CRM icon
Salesforce
CRM
+$181M
4
QGEN icon
Qiagen
QGEN
+$123M
5
CZR
Caesars Entertainment Corporation
CZR
+$97.2M

Sector Composition

Rank Sector Weight
1 Healthcare 40.81%
2 Communication Services 17.58%
3 Technology 8.21%
4 Financials 7.39%
5 Industrials 5.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLGX
76
DELISTED
Corelogic, Inc.
CLGX
$23.3M 0.16%
+345,000
New +$23.2M
BEKE icon
77
KE Holdings
BEKE
$18.8B
$20.5M 0.14%
+335,000
New +$16.7M
KRYS icon
78
Krystal Biotech
KRYS
$9.66B
$20.4M 0.14%
475,000
+25,000
+6% +$1.09M
ADAP
79
DELISTED
Adaptimmune Therapeutics
ADAP
$20.1M 0.14%
2,515,762
+15,762
+0.6% +$138K
ZEAL
80
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$19.2M 0.13%
505,000
+5,000
+1% +$181K
ARWR icon
81
Arrowhead Research
ARWR
$12.4B
$18.2M 0.13%
423,600
-376,400
-47% -$16.2M
PLRX icon
82
Pliant Therapeutics
PLRX
$65M
$17.3M 0.12%
764,262
-86,539
-10% -$2.16M
DCPH
83
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$16.9M 0.12%
330,000
-385,000
-54% -$18.9M
QURE icon
84
uniQure
QURE
$3.22B
$16.6M 0.11%
450,000
+150,000
+50% +$6.15M
ADVM
85
DELISTED
Adverum Biotechnologies
ADVM
$15.4M 0.11%
+150,000
New +$22.5M
RC
86
Ready Capital
RC
$308M
$15.1M 0.1%
1,350,226
– –
AUPH icon
87
Aurinia Pharmaceuticals
AUPH
$2.11B
$14.7M 0.1%
+1,000,000
New +$14.5M
DMTK
88
DELISTED
DermTech, Inc. Common Stock
DMTK
$14.6M 0.1%
1,219,999
+1,025,324
+527% +$11.9M
TECX
89
Tectonic Therapeutic
TECX
$606M
$13.7M 0.09%
87,500
-43,750
-33% -$8.81M
CMPS
90
Compass Pathways
CMPS
$1.83B
$12.7M 0.09%
+362,940
New +$13M
NAV
91
DELISTED
Navistar International
NAV
$12M 0.08%
+276,600
New +$9.49M
ATTO
92
DELISTED
Atento S.A.
ATTO
$12M 0.08%
2,230,357
– –
HZNP
93
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.7M 0.08%
+150,000
New +$10.3M
WTW icon
94
Willis Towers Watson
WTW
$32B
$10.4M 0.07%
+50,000
New +$10.2M
RCUS icon
95
Arcus Biosciences
RCUS
$3.64B
$9.43M 0.07%
550,000
-450,000
-45% -$10.1M
LQDA icon
96
Liquidia Corp
LQDA
$8.02B
$9.18M 0.06%
1,865,350
+15,350
+0.8% +$88.8K
TARA icon
97
Protara Therapeutics
TARA
$232M
$7.15M 0.05%
+425,000
New +$9.86M
INBX
98
DELISTED
Inhibrx, Inc. Common Stock
INBX
$7.11M 0.05%
+395,000
New +$7.16M
ALBO
99
DELISTED
Albireo Pharma Inc
ALBO
$6.67M 0.05%
+200,000
New +$5.83M
ALPN
100
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.52M 0.05%
+741,290
New +$6.78M
2 3
4
5 6

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Farallon Capital Management held 146 positions worth $14.5B, up 16% from $12.5B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Farallon Capital Management deployed $582M of net new capital in Q3 2020, opening 31 new positions and adding to 52 existing holdings. Its largest new stake was Boston Scientific: 8,275,919 shares worth $316M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 43% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Salesforce, an estimated $181M trimmed.

  • Farallon Capital Management's largest Q3 2020 buy was Boston Scientific: 8,275,919 shares worth $316M.
  • Farallon Capital Management added most to Alphabet (Google) Class C in Q3 2020, an estimated $216M increase.
  • Farallon Capital Management's biggest Q3 2020 reduction was Salesforce, cutting an estimated $181M.
  • Farallon Capital Management fully exited People Inc in Q3 2020, selling an estimated $456M.
  • Farallon Capital Management's ten largest holdings make up 32% of its $14.5B portfolio in Q3 2020.
  • Farallon Capital Management opened 31 new positions and closed 24 in Q3 2020.
  • Farallon Capital Management's portfolio value rose 16% quarter-over-quarter to $14.5B.

Based on Farallon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.